BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29560112)

  • 21. Profile of common prostate cancer risk variants in an unscreened Romanian population.
    Iordache PD; Mates D; Gunnarsson B; Eggertsson HP; Sulem P; Guðmundsson J; Benónísdóttir S; Csiki IE; Rascu S; Radavoi D; Ursu R; Staicu C; Calota V; Voinoiu A; Jinga M; Rosoga G; Danau R; Sima SC; Badescu D; Suciu N; Radoi V; Manolescu A; Rafnar T; Halldórsson BV; Jinga V; Stefánsson K
    J Cell Mol Med; 2018 Mar; 22(3):1574-1582. PubMed ID: 29266682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
    Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
    Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.
    Helfand BT; Loeb S; Cashy J; Meeks JJ; Thaxton CS; Han M; Catalona WJ
    J Urol; 2008 Jun; 179(6):2197-201; discussion 2202. PubMed ID: 18423739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men.
    Li XH; Xu Y; Yang K; Shi JJ; Zhang X; Yang F; Yuan H; Zhu X; Zhang YH; Wang JY; Yang Z
    J BUON; 2015; 20(5):1223-8. PubMed ID: 26537068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
    Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
    Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
    Troutman SM; Sissung TM; Cropp CD; Venzon DJ; Spencer SD; Adesunloye BA; Huang X; Karzai FH; Price DK; Figg WD
    Oncologist; 2012; 17(3):312-20. PubMed ID: 22382457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.
    Marra G; Valerio M; Heidegger I; Tsaur I; Mathieu R; Ceci F; Ploussard G; van den Bergh RCN; Kretschmer A; Thibault C; Ost P; Tilki D; Kasivisvanathan V; Moschini M; Sanchez-Salas R; Gontero P; Karnes RJ; Montorsi F; Gandaglia G;
    Eur Urol Oncol; 2020 Oct; 3(5):565-581. PubMed ID: 32933887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
    Nordström T; Van Blarigan EL; Ngo V; Roy R; Weinberg V; Song X; Simko J; Carroll PR; Chan JM; Paris PL
    Prostate; 2016 Mar; 76(4):339-48. PubMed ID: 26585352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.
    Chen H; Yu H; Wang J; Zhang Z; Gao Z; Chen Z; Lu Y; Liu W; Jiang D; Zheng SL; Wei GH; Issacs WB; Feng J; Xu J
    Prostate; 2015 Sep; 75(12):1264-76. PubMed ID: 26015065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer.
    Chen H; Liu W; Roberts W; Hooker S; Fedor H; DeMarzo A; Isaacs W; Kittles RA
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):238-43. PubMed ID: 20634801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians.
    Shan J; Al-Rumaihi K; Rabah D; Al-Bozom I; Kizhakayil D; Farhat K; Al-Said S; Kfoury H; Dsouza SP; Rowe J; Khalak HG; Jafri S; Aigha II; Chouchane L
    J Transl Med; 2013 May; 11():121. PubMed ID: 23668334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic factors influencing prostate cancer risk in Norwegian men.
    Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
    Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.
    He Y; Gu J; Strom S; Logothetis CJ; Kim J; Wu X
    Clin Cancer Res; 2014 Oct; 20(19):5133-5139. PubMed ID: 25274378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.
    Wang Q; Gregg JR; Gu J; Ye Y; Chang DW; Davis JW; Thompson TC; Kim J; Logothetis CJ; Wu X
    Oncoimmunology; 2019; 8(1):e1483303. PubMed ID: 30546938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.